Skip to main content
SpringerLink
Log in

Multiples Myelom

Diagnose und Klinik

Multiple myeloma

Diagnosis and clinical picture

  • Leitthema
  • Published:
Der Onkologe Aims and scope

Zusammenfassung

Das multiple Myelom (MM) gehört zu den 20 häufigsten Tumorerkrankungen in Deutschland. Die initialen Symptome des MM sind meist uncharakteristisch. Labor- und Knochenmarkdiagnostik sowie Bild gebende Verfahren sind essenziell für Diagnosestellung und Prognoseabschätzung. Die Diagnosesicherung ist bisher nicht standardisiert. Molekularbiologische und zytogenetische Befunde ermöglichen ein besseres Verständnis der Pathogenese und erlangen zunehmend Bedeutung zur Prognosebestimmung. Die klassische Einteilung des MM nach Durie und Salmon in 3 Stadien ist weltweit akzeptiert. Neue Stadienzuordnungen werden geprüft.

Abstract

Multiple myeloma (MM) is one of the 20 most frequent malignancies in Germany. Initial symptoms of MM are mostly nonspecific. Clinical chemistry and bone marrow diagnostics as well as imagnig techniques are essential for the diagnosis of MM and for predicting the clinical outcome. Up to now, diagnostic criteria for MM have not been standardized. Results from molecular biological and cytogenetic investigations aid in understanding the pathogenesis of MM and are increasingly used for assessing the prognosis of patients. The classic staging system according to Durie and Salmon has been accepted globally. New staging systems are currently being evaluated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5
Abb. 6a, b

Literatur

  1. Barlogie B, Shaughnessy J, Tricot G et al. (2004) Treatment of multiple myeloma. Blood 103:20–32

    Article  CAS  PubMed  Google Scholar 

  2. Barlogie B, Alexanian R, Jagannath S (1992) Plasma cell dyscrasias. JAMA 268 (20):2946–2951

    Article  CAS  PubMed  Google Scholar 

  3. Bartl R, Frisch B (1998) Bone marrow biopsy and aspiration for diagnosis of multiple myeloma. In: Malpas JS, Bergsagel DE, Kyle R, Anderson K (eds) Myeloma: Biology and Management, 2nd ed. Oxford Medical Publications, Oxford New York

  4. Baur A, Stäbler A, Nagel D et al. (2002) Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon. Cancer 95:1334–1345

    Article  PubMed  Google Scholar 

  5. Dietzfelbinger H, Wick M, Bartl R, Lamerz R (2002) Prognostische Faktoren. In: Bartl R (Hrsg) Manual—Multiples Myelom—Empfehlungen zur Diagnostik, Therapie und Nachsorge. Zuckschwerdt, München Wien New York, S 79–86

  6. Drayson M, Tang LX, Drew R et al. (2001) Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 97:2900–2902

    Article  CAS  PubMed  Google Scholar 

  7. Durie BGM (1986) Staging and kinetics of multiple myeloma. Semin Oncol 13:300–309

    CAS  PubMed  Google Scholar 

  8. Durie BGM, Kyle RA, Belch A et al. (2003) Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 4:379–398

    Article  PubMed  Google Scholar 

  9. Durie BGM, Salmon SE (1975) A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842–854

    CAS  PubMed  Google Scholar 

  10. Durie BGM, Waxman AD, D’Angelo A et al. (2002) Whole-body18F-FDG PET identifies high-risk myeloma. J Nucl Med 43:1457–1463

    PubMed  Google Scholar 

  11. Goldschmidt H, Cremer FW (2002) Das Multiple Myelom (Plasmozytom)—Diagnose und Therapie. Uni Med, Bremen London Boston

  12. Goldschmidt H, Lannert H, Bommer J, Ho AD (2000) Multiple myeloma and renal failure. Nephrol Dial Transplant 15:301–304

    Article  CAS  PubMed  Google Scholar 

  13. Greipp PR et al. (2003) Development of an International Prognostic Index (IPI) for myeloma: Report of the International Myeloma Working Group. Haematol J 4:42–45

    Google Scholar 

  14. Kusumoto S, Jinnai I, Itoh K et al. (1997) Magnetic resonance imaging patterns in patients with multiple myeloma. Br J Haematol 99:649–655

    Article  CAS  PubMed  Google Scholar 

  15. Kyle RA, Child JA, Durie BGM et al. (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma, and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121:749–757

    PubMed  Google Scholar 

  16. Kyle RA, Greipp PR (1980) Smoldering multiple myeloma. New England J Med 302:1347–1349

    CAS  Google Scholar 

  17. Kyle RA, Therneau TM, Rajkumar SV et al. (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346:564–569

    Article  PubMed  Google Scholar 

  18. Ludwig H, Meran J, Zojer N (1999) Multiple myeloma: an update on biology and treatment. Ann Oncol 10 (Suppl 6):31–43

    Article  PubMed  Google Scholar 

  19. Ossermann EF (1959) Plasma cell myeloma: II. Clinical aspects. New Engl J Med 261:952–960

    PubMed  Google Scholar 

  20. Tarte K, Zhan F, De Vos J et al. (2003) Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the stages of B-cell differentiation. Blood 102:592–600

    Article  CAS  PubMed  Google Scholar 

  21. Woodruff RK, Wadsworth J, Malpas JS, Tobias JS (1979) Clinical staging in multiple myeloma. Br J Haematol 42:199–205

    CAS  PubMed  Google Scholar 

  22. Zhan F, Barlogie B, Shaughnessy J (2003) Toward the identification of distinct molecular and clinical entities multiple myeloma using global gene expression profiling. Semin Hematol 40:308–320

    CAS  PubMed  Google Scholar 

Download references

Interessenkonflikt:

Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.

Author information

Authors and Affiliations

  1. Medizinische Klinik und Poliklinik V, Universität Heidelberg

    H. Goldschmidt, F. W. Cremer & T. M. Möhler

  2. Medizinische Klinik und Poliklinik V, Universität Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg

    H. Goldschmidt

Authors
  1. H. Goldschmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. W. Cremer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. M. Möhler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Goldschmidt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goldschmidt, H., Cremer, F.W. & Möhler, T.M. Multiples Myelom. Onkologe 10, 809–819 (2004). https://doi.org/10.1007/s00761-004-0751-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-004-0751-y

Schlüsselwörter

Keywords

Search

Navigation